Immunogenicity of a 16.7kDa Mycobacterium paratuberculosis antigen

Mullerad, Jacob; Hovav, Avi‐Hai; Nahary, Ronen; Fishman, Yolanta; Bercovier, Hervé

doi:10.1016/s0882-4010(02)00209-7

Cited by 21 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The his-16.8 kDa fusion protein was expressed in M 15 E. coli host strain. The presence of 6X-histidine residues at N-terminal of the fusion protein enabled us to purify the protein by single step affinity purification by using Ni-NTA resin, as also used by other workers (Mukhija et al 1995;Pillai et al 1996;Goswami et al 1996).The size of the protein observed in this experiment was similar as observed by other scientists (Mullerad et al 2003). In our experience the recovery of the purified protein was more than 90% after 6 hours of induction.…”

Section: Discussionsupporting

confidence: 79%

Coexpression of 16.8 kDa antigen of Mycobacterium avium paratuberculosis and murine gamma interferon in a bicistronic vector and studies on its potential as DNA vaccine

et al. 2009

View full text Add to dashboard Cite

Paratuberculosis or Johne's disease is a chronic gastric disease of ruminants. For this disease there is no effective treatment or preventive measure available. 16.8 kDa protein is an immunogenic protein of Mycobacterium avium paratuberculosis and can be an ideal candidate for developing a DNA vaccine construct. In present study a bicistronic DNA vaccine construct pIR16.8/IFN was developed using eukaryotic vector pIRES 6.1. Two genes MPT (expressing 16.8 kDa protein) and murine IFNgamma were cloned, expressed and immunoreactivity was studied in murine model. Immunoreactivity was also compared with monocistronic construct pIR16.8 expressing 16.8 kDa protein. Both pIR16.8 and pIR16.8/IFN showed eukaryotic expression of respective proteins in BHK21 cells. The expressed proteins also showed immunoreactivity when reacted with hyperimmune sera raised against recombinant 16.8 kDa protein in western blot assay and immunofluorence assay. Both constructs were used as DNA vaccine in murine model and immunogenecity was studied by DTH, lymphocyte proliferation assay and NO determination. DTH reaction was significantly high in pIR16.8/IFN than pIR16.8 group, similarly lymphocyte proliferation and NO release was higher in pIR16.8/IFN group than pIR16.8 group. This indicated T cell epitopic nature of 16.8 kDa protein. The study also showed that co-expression of IFNgamma with mycobacterial gene can enhance immunogenecity of DNA vaccine and can be used as immunoadjuvant.

show abstract

Section: Discussionsupporting

confidence: 79%

Coexpression of 16.8 kDa antigen of Mycobacterium avium paratuberculosis and murine gamma interferon in a bicistronic vector and studies on its potential as DNA vaccine

et al. 2009

View full text Add to dashboard Cite

show abstract

“…It is generally believed that reactive nitrogens, such as NO, are most effective in direct killing of mycobacteria [38]. Significantly higher NO concentration was seen in vaccinated groups (maximum in “Bison” group and least for “sham-immunized” group).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Effects of a New “Indigenous Vaccine” Developed Using Novel Native “Indian Bison Type” Genotype ofMycobacterium aviumSubspeciesparatuberculosisfor the Control of Clinical Johne's Disease in Naturally Infected Goatherds in India

Singh

et al. 2010

Veterinary Medicine International

View full text Add to dashboard Cite

Therapeutic efficacy of an “Indigenous vaccine” has been evaluated with respect to a commercial vaccine (Gudair, Spain), for the control of clinical Johne's disease (JD) in naturally infected goatherds. Seventy-one goats (JD positive) were randomly divided into 3 groups (“Bison”, “Gudair” and “Sham-immunized”). After vaccination, goats were monitored for physical condition, morbidity, mortality, body weights, shedding of M. paratuberculosis (MAP) in feces, internal condition and lesions, as well as humoral and cell-mediated immune responses for 210 days. Study showed marked overall improvement in physical condition of vaccinated goats and average body weight gain was significantly higher (P < .05) in “Bison” group as compared to “Sham-immunized” goats. Mortality due to JD was significantly (P < .05) lower in vaccinated groups than in “sham-immunized”. Morbidity rates (due to diarrhea and weakness) were lower in “Bison” group as compared to other groups. Died goats from vaccinated groups showed regression of gross JD lesions and regeneration of fat layer around visceral organs while “Sham-immunized” goats exhibited frank lesions. Vaccinated goats had higher protective CMI response and also higher antibody titer for the trial period as compared to “Sham immunized”. Both vaccines also reduced shedding of MAP in feces significantly (P < .05). Though the two vaccines effectively restricted the severity of clinical symptoms of JD, however “Indigenous vaccine” was superior in many respects.

show abstract

“…The alkyl hydroperoxide reductase proteins (AhpC and AhpD), likely involved in the detoxification of reactive nitrogen intermediates, are also abundant immunogenic proteins of MAP in sterling contrast to their low abundance in MAV when both microorganisms are grown under various laboratory conditions (124). Other immunogenic proteins shared by mycobacteria and secreted by MAP include a 32-kDa antigen (56), a 16.7-kDa antigen, and a manganese-dependent superoxide dismutase (SodA), and proteins of the antigen 85 complex (49,101,110). Antigens 16.7, 85B, and SodA from MAP elicit T helper 1 (Th1)-type immune responses associated with protective immunity in mice (109)(110)(111).…”

Section: Antigens and Virulence Determinantsmentioning

confidence: 99%

“…Other immunogenic proteins shared by mycobacteria and secreted by MAP include a 32-kDa antigen (56), a 16.7-kDa antigen, and a manganese-dependent superoxide dismutase (SodA), and proteins of the antigen 85 complex (49,101,110). Antigens 16.7, 85B, and SodA from MAP elicit T helper 1 (Th1)-type immune responses associated with protective immunity in mice (109)(110)(111). Protein antigens of 34.5 and 44.3 kDa have also been identified in culture filtrates of MAP by the use of monoclonal antibodies against MAP antigens, though no sequence data are available on these antigens (112).…”

Section: Antigens and Virulence Determinantsmentioning

confidence: 99%

Johne's Disease, Inflammatory Bowel Disease, andMycobacterium paratuberculosis

Chacón

Bermudez

Barletta³

2004

Annu. Rev. Microbiol.

207

148

View full text Add to dashboard Cite

Johne's disease is a chronic diarrhea affecting all ruminants. Mycobacterium avium subsp. paratuberculosis (MAP), a slowly growing mycobacteria, is the etiologic agent. There is also a concern that MAP might be a causative agent of some cases of inflammatory bowel disease in humans, especially Crohn's disease. Food products including pasteurized bovine milk have been suggested as potential sources of human infection. This review addresses microbial factors that may contribute to its pathogenicity. In addition, the experimental evidence defining MAP as the cause of Johne's disease and the issues and controversies surrounding its potential pathogenic role in humans are discussed.

show abstract

Immunogenicity of a 16.7kDa Mycobacterium paratuberculosis antigen

Cited by 21 publications

References 36 publications

Coexpression of 16.8 kDa antigen of Mycobacterium avium paratuberculosis and murine gamma interferon in a bicistronic vector and studies on its potential as DNA vaccine

Coexpression of 16.8 kDa antigen of Mycobacterium avium paratuberculosis and murine gamma interferon in a bicistronic vector and studies on its potential as DNA vaccine

Therapeutic Effects of a New “Indigenous Vaccine” Developed Using Novel Native “Indian Bison Type” Genotype ofMycobacterium aviumSubspeciesparatuberculosisfor the Control of Clinical Johne's Disease in Naturally Infected Goatherds in India

Johne's Disease, Inflammatory Bowel Disease, andMycobacterium paratuberculosis

Contact Info

Product

Resources

About